Why the study?
Does the combination of subcutaneous erythropoietin and intravenous iron improve clinical and functional outcomes in anemic patients with severe resistant congestive heart failure?
Population
Anemic patients with severe congestive heart failure resistant to maximally tolerated CHF medications
Design
Review
Authors
Loading...
May support anemia correction in severe resistant HF; leaves open confirmation in randomized trials.
Does the combination of subcutaneous erythropoietin and intravenous iron improve clinical and functional outcomes in anemic patients with severe resistant congestive heart failure?
Correction of anemia using erythropoietin and intravenous iron in severe, resistant heart failure may improve functional status, cardiac function, and reduce hospitalizations, though larger confirmatory studies are needed.
Dov Wexler (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: